Automation was aimed at repeatable work inside the approved content lifecycle, leaving human and MLR authority unchanged.
Pfizer · Content Automation
Challenge
Teams rebuilt work that already existed in approved form, because finding and reusing an approved component was harder than producing a new one. Review capacity — the scarcest thing in a regulated content operation — was being spent on variation that served no purpose, and the same review effort recurred every cycle.
Action
The operating design made reuse the easier path rather than the encouraged one: approved components were structured so they could be consumed directly, and review outcomes were captured so each cycle informed the next instead of starting cold. Human approval was deliberately preserved wherever medical or regulatory judgment was required — the automation took the repetition, not the decision, which is what kept MLR control intact while throughput changed. The Value, Quality and Improvement Review closed the loop: value demonstrated, failures fed back, and the next improvement cycle funded on evidence rather than on argument.
Result
Review-cycle speed improved by 35% and approved-content reuse increased 2.3 times, with human approval and MLR controls unchanged. The gain came from removing avoidable production work rather than from relaxing review: the same judgment was applied to less repeated effort. Human approval stayed where regulatory judgment was required, so the throughput gain did not come at the cost of control.
